Novavax completes construction of vaccine facility

Novavax officials announced this week that they have completed construction of a new vaccine facility in India.

The new, state-of-the-art facility will have the capability to efficiently produce up to 60 million doses of new vaccines annually, a company spokesman said.

A.I. Modi, chairman of Cadila Pharmaceuticals, which embarked on the joint effort with Novavax, said he is excited about the completion of the project.

“This facility demonstrates our commitment to establishing the highest-quality vaccine production facility for our nation,” Modi said. “It utilizes world-class design and equipment that will be competitive with the world's leading vaccine companies.”

Officials said that the facility will produce seasonal and pandemic flu vaccines based on Novavax's advanced virus-like particle technology.

Novavax president and CEO Dr. Rahul Singhvi said he is excited about the new facility and its capabilities.

“We congratulate our colleagues at CPL Biologicals on reaching this important milestone in the development of a state-of-the-art vaccine production facility,” Singhvi said. “This achievement reflects our strategy to partner with leading pharmaceutical companies around the world to develop world-class, in-country vaccine-production capacity and use our novel vaccine technology to solve critical public health problems. This world class vaccine production plant in India will be able to supply India and other countries with novel vaccines against influenza and other infectious diseases by using an efficient, reliable and flexible vaccine production process.”